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Abstract
Human disease studies using DNA microarrays in both clinical/observational and experimental/controlled studies are having
increasing impact on our understanding of the complexity of human diseases. A fundamental concept is the use of gene
expression as a ‘‘common currency’’ that links the results of in vitro controlled experiments to in vivo observational human
studies. Many studies – in cancer and other diseases – have shown promise in using in vitro cell manipulations to improve
understanding of in vivo biology, but experiments often simply fail to reflect the enormous phenotypic variation seen in
human diseases. We address this with a framework and methods to dissect, enhance and extend the in vivo utility of in vitro
derived gene expression signatures. From an experimentally defined gene expression signature we use statistical factor
analysis to generate multiple quantitative factors in human cancer gene expression data. These factors retain their
relationship to the original, one-dimensional in vitro signature but better describe the diversity of in vivo biology. In a breast
cancer analysis, we show that factors can reflect fundamentally different biological processes linked to molecular and
clinical features of human cancers, and that in combination they can improve prediction of clinical outcomes.
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Introduction
Microarray technology allows the capture of diverse aspects of
genetic, environmental, oncogenic and other factors as reflected in
global mRNA expression and opens the possibility of personalizing
treatment of disease [1,2]. Multiple studies have taken a ‘‘top-
down’’ approach to profiling gene expression in human cancers,
and this has led to the identification of tumor subtypes
unrecognized previously as well as gene signatures predicting
various clinical phenotypes [3–7]. Alternatively, other studies have
taken a ‘‘bottom-up’’ approach to determine the change of gene
expression caused by specific manipulations of cultured cells in
vitro. In these studies gene expression serves as a common
phenotype to recognize similar features in human cancers in vivo
and to provide a direct linkage between the known biological
perturbation and the clinical contexts [8–12].
Though many such studies have shown promise in using in vitro
cell manipulations to understand in vivo biology, this approach
cannot fully reflect the enormous phenotypic variation seen in
human cancers. From such studies, one can derive signatures. These
we define to be lists of genes that are differentially expressed along
with their associated levels of differential expression (which we call
weights). However, there is nearly always a poor match between
these signatures and expression patterns of the same genes in vivo.
Therefore, a conceptual framework is needed to further dissect,
enhance and extend the in vivo utility of the in vitro derived
signature. Here, we present a technique for achieving this purpose.
We propose deriving multiple factors, based on human cancer
gene expression studies, from an experimentally defined signature.
These derived factors will retain their relationship to the original
signature but represent distinct biological processes. Importantly,
we show that different derived factors can be combined to provide
much better predictive values for the clinical outcomes. Different
factors also reflect different biological processes and are linked to
various aspects of molecular and clinical features of human
cancers.
There are a number of possible approaches to this problem.
One popular approach has been to compare the identities of the
differentially expressed probes to databases of pre-defined
pathways. Descriptions of such approaches can be found in [13–
15]. While these approaches are appealing for their interpretabil-
ity, they rely on the appropriately pre-defined pathways rather
than the structure of the data under study. Alternatively, one may
simply define the signature activity level for a sample as the
weighted average of in vivo expression levels (where the genes over
which to compute the weights and the weights themselves are
drawn from the original signature). Although some studies have
shown the power of this concept, it is clear that one can not hope
to capture the heterogeneity of in vivo biology from the one-
dimensional controlled biological response the in vitro signature
reflects.
The inherent heterogeneity of environment and cell type in
tissue samples means that the genes in a signature may potentially
involve many additional activities not evident in vitro. Further,
experiments on cloned cell lines of a single cell type grown under
tightly controlled conditions for a fixed (and relatively short) length
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living organisms containing multiple cell types that have been in a
dynamic environment for months or years. There is no clearly
‘‘correct’’ method for taking what is learned by microarray
experiment in culture and applying it to assess pathway activity in
tissuesamples.Somegenesmaybepoorerrepresentativesofpathway
activity in vivo because they are more likely to be involved in other
pathways, because they react to environmental conditions that are
not present in vitro, or for a myriad of other reasons. It is, therefore,
important to provide a statistical and conceptual framework which
canallowustousetheinvivoexpressiondatatofurtherdissect,refine
and enhance the in vitro-derived gene signatures.
Signature Factor Profiling Analysis (SFPA), based on sparse statistical
factor models, [16,17] is a framework for mapping in vitro
signatures to a collection of in vivo factors. While this sounds
similar to hierarchical clustering (which has become the default
method for this type of problem), there are important distinctions.
First, while hierarchical clustering can be used to break a set of
samples into groups, within which expression patterns are similar
in some way, it does not quantify that similarity. Second,
hierarchical clustering requires that each observation (gene) be a
member of just one cluster. This precludes assigning clusters to
biological pathways, because many combinations of pathway
activity are possible. Lastly, because the factors are generated
within a statistical model, it is possible to identify the levels of
activity in each of the factors on a newly measured sample without
redoing the statistical analysis. While there are techniques other
than hierarchical clustering which address some of these issues, for
example soft-clustering [18] and k-means clustering [19], our
algorithm addresses them all within a single coherent statistical
framework. SFPA provides:
N Robust statistical modeling of both experimental gene
expression and tissue sample expression.
N Identification and correction of assay artifacts, which are
known to be a significant issue associated with the use of
microarray technologies.
N A mapping from a single signature, generated in vitro,t oa
collection of factors that retain the pertinent characteristics of
the signature while better reflecting heterogeneity in vivo
associated with the biological perturbation the signature
represents.
N A model for imputing the values of factors in new collections of
tissue samples even though these samples may originate from
different groups and at different times.
We explore this analysis approach in translating a collection of
gene signatures reflecting cellular response to five known tumor
microenvironmental factors, discovered in vitro [8], with particular
emphasis on the signature associated with response to lactic
acidosis. We demonstrate that multiple factors arising in a breast
cancer context remain representative of the individual microen-
vironmental pathway responses from which they are derived.
Furthermore, these factors differentiate key biological phenotypes
in breast cancer, are able to improve clinical predictions across
multiple cancer data sets, and retain their predictive ability even
when applied to samples taken at vastly different times or at
different study centers.
Results
Context, Data and Analysis Strategy
We begin with five signatures defined by the transcriptional
responses of cultured human mammary breast epithelial cells to
five microenvironmental perturbations: hypoxia, lactic acidosis,
hypoxia plus lactic acidosis, lactosis, and acidosis. Each of these is
seen in human cancers and carries prognostic information with
respect to clinical outcomes [8]. The signatures represent changes
in expression of genes between a set of control observations and
cells grown in the presence of lactic acidosis (25 mM lactic acid,
pH 6.7), hypoxia (2% O2), lactic acid plus hypoxia, lactosis
(25 mM sodium lactate, neutral pH), and acidosis (pH 6.7 without
lactate). Expression assays used Affymetrix U133+ 2.0 microarrays
and signatures reflecting each of the microenvironmental factors
have been described [8]. As shown in [8], hypoxia, lactic acidosis
and acidosis have strong prognostic significance in several studies
of breast cancers. Our aim here is to explore the various
components of the original gene signatures to evaluate the
opportunity for further enhancing their prognostic values and
dissecting them into distinct biological pathway-relevant factors
with clinical relevance.
We use Bayesian Factor Regression Modeling (BFRM) [20] to
define and estimate factors based on a given signature. This begins
with a small collection of genes that are highly responsive to the
original intervention (highly differentially expressed between
control and experimental groups in cell culture) and then
iteratively refines the gene set, based on co-expression in an in
vivo data set, in the context of a statistical factor analysis. First,
common patterns of expression (factors) are discovered within
the subset of genes currently under consideration. Next, the
association between these factors and the full set of genes on the
array allows us to identify additional genes to be included in a
revision of the factor analysis. The rationale for this is that, while
evaluating factors underlying the initial selected signature genes
allows us to elucidate in vivo variability that is not present in vitro,
adding genes from outside the original signature can improve the
characterization of these factors while providing linkages to other
relevant pathways. Running SFPA on each of the five signatures
independently, we obtain 11 hypoxia factors, 10 lactic acidosis
factors, 20 hypoxia plus lactic acidosis factors, 17 lactosis factors
and 9 acidosis factors. SFPA stops discovering factors once most of
the variability in the original gene set has been explained.
Signature-Factor Relationships
We will focus, for now, on the ten lactic acidosis factors.
Examining the genes in each of the factors (Figure 1a) shows that
all factors have representatives from the original signature in
addition to genes added during the process of fitting the factor
model. It is important to be sure that in the discovery of these ten
factors, we have not lost our original signature. We check this by
regressing the 10 sets of derived factor scores on the lactic acidosis
signature scores. (Calculation of a signature score is described in
the Methods section.) Witin a single multivariate regression model,
we find that 7 of the 10 are significant at the .01 level, and that
when we eliminate the remaining three factors from the
multivariate regression, those seven remain significant. Thus, at
least seven of the factors show a significant association to the
original signature.
Figure 1b shows the fitted values from the regression of the
lactic acidosis signature score on the lactic acidosis factors from the
analysis of the 251 tumor sample data set from [21]. The r2 for this
regression is high (.74), but it is possible these ten factors might be
able to explain many different signatures. In order to show that
this is not a spurious association, we test the hypothesis that this r2
level is independent of which genes are assigned which weights.
We re-sampled the weights 10,000 times, each time regressing the
signature score vector computed from these weights on the 10
lactic acidosis factors and computing an r2 value. Of the 10,000
Cross-Study Projections
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was .48 ensuring that the p-value %10
24. If we approximate the
distribution of r2 values by a beta distribution (calculated by
method of moments) we get a very close fit (see Figure S1) and
estimate the p-value to be <10
213. Because only the list of highly
differentially expressed genes from the lactic acidosis signature,
Figure 1. Factor associations. (a) Connections between genes and the 10 lactic acidosis factors in the statistical factor analysis of the breast cancer
data from [21]. The genes include the initial selected signature genes (black) and those added through the iterative enrichment analysis (red), with
black or red indicating that a gene (row) is highly associated with a factor (column), and white indicating little or no association. Cross-talk between
putative pathway-related factors and genes is evident. (b) Lactic acidosis signature (vertical axis) is predicted by a linear regression fit (horizontal axis)
on the seven factors significantly associated with the lactic acidosis signature. (c) Image of thresholded correlations between 67 factors (vertical) and
the 10 lactic acidosis factors (horizontal), with black indicating pairs of factors whose pairwise sample correlation exceeds 0.9 in absolute value.
doi:10.1371/journal.pone.0004523.g001
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the weights are critical for the computation of the lactic acidosis
signature scores, the ability to recover signature scores from factors
is strong evidence of the relationship between the two.
The three factors derived from the lactic acidosis signature that
were not important in the prediction of signature scores may still
represent activity relevant to the presence of lactic acid, but they
are not strongly predictive of the original signature. They may also
simply represent the activity of biological pathways that involve
very large sets of genes, and are thus discovered from many
different possible starting points. Nonetheless, they represent
significant structure in expression of the expanded signature gene
set in tumor data, and none of these factors would be detectable
from studying the signature alone as a phenotype.
Factors can reflect distinct aspects of biological activity.
Figure 1c shows which of the 67 factors (all factors discovered
from each of the five starting signatures) have high correlation with
the 10 lactic acidosis factors from the Miller breast data analysis
[21]. Notice that no two of the lactic acidosis factors are highly
correlated, thus these factors seem to describe distinct processes.
Some of the 10 factors, such as lactic acidosis factor 8 for example,
are highly correlated with multiple other factors, indicating that
these factors have been identified from multiple initial signatures.
Most, however, show low levels of pairwise correlation. Among the
67 factors, 40 principal components are required to account for
95% of the observed variability (supplementary figure S2) implying
that a relatively high biological ‘‘dimension’’ underlies the 67
factors – they reflect a diverse set of biological activities, and
presumably pathways altered in the cellular responses to lactic
acidosis within human breast tumors. Figure 1a shows the
connections between genes and the 10 lactic acidosis factors in
the analysis. The genes include the initial selected signature genes
and those added through the iterative enrichment analysis. The
SFPA-derived factors retain a high percentage of genes that have
been shown to exhibit a change in expression when cells are
exposed to the presence of lactic acid in vitro, showing in another
way that these factors still maintain their connection with the
original signature. The cross-talk between factors, in terms of
genes defining more than one factor, is also evident.
Factors Predict Molecular Features
SFPA-derived factors can represent distinct aspects of biological
processes associated with clinical phenotypes. To evaluate this, we
explored subset regression models to predict a number of clinical
phenotypes in the Miller data set [21] - the phenotypes including
ER and PgR status, p53 status and survival times. The molecular
status indicators were modelled with binary probit regressions on
the factors, and survival with standard Weibull survival models.
We utilized the Shotgun Stochastic Search (SSS) method [22,23]
to identify small subsets of the factors showing predictive value
with respect to each of these phenotypes. SSS is a variable
selection model which allows the use of model averaging (based on
posterior likelihood) for prediction. Model averaging has been
shown to perform better than algorithms which use the single best
model for prediction (such as AIC or BIC) because it gives a truer
estimation of uncertainty [24]. This analysis was performed on the
data set from [21], and then the resulting fitted/trained regression
models were used to predict phenotypes in each of five separate
and biologically diverse breast cancer data sets [25–28]. All data
sets are available from the Gene Expression Omnibus (GEO).
Factors predict ER status. The analysis indicates that
highly scoring regression models for the prediction of ER status
utilize one of the factors – Acidosis 1, Hypoxia 4, Lactic Acidosis 2,
or Lactosis 5. From Figure 2a, one can see that the correlation
between any two of these factors is high, so we will refer to them
collectively as the ER factors. Figure 3a demonstrates the ability of
this factor to predict ER status on the training set [21] and 3b
shows prediction on a distinct and completely unrelated test set
[27]. To examine the gene ontology (GO) composition of the list of
genes involved in the ER factors, we applied the GATHER
analysis [29] and find that GO terms associated with cell cycle,
proliferation and and mitosis are greatly enriched in these factors
(Table 1), corroborating well-known connection between cell
progression and ER. It is also expected that the presence of lactic
acid or hypoxia acts to shut down the cell cycle and the ER factor
appears to directly link the two processes.
Factors predict PgR status. Estrogen and progesterone are
known to be antagonists, so it is expected that ER factors can
predict progesterone receptor status. Using SSS we find that the
highly scoring regression models for PgR status involve the ER
factor in addition to Lactic Acidosis factor 10 – we label this the
PgR specific factor. Figures 3c and 3d show the fitted and
predictive ability of these two factors used in a binary regression
model fit to progesterone receptor status. There is no significant
correlation in tumor expression between the PgR and ER factors
(Figure 2b). Gene ontology for the genes in the PgR specific factor
(Table 2) bear out some of the known links between progesterone
and RNA metabolism in breast cancer [30].
Factors predict p53 status. The third binary phenotype,
wild type versus mutant p53 gene, is present in only the data set
from [21]. SFPA was re-run on a randomly selected 50% of these
data and used to predict the other 50% (Figure 3). Highly scored
models for p53 involve the ER factor, the PgR specific factor, and
one of either Hypoxia 1 or Lactic Acidosis 3. The correlation
between these latter two factors is 99%, so we label them
collectively as the p53 specific factor. Gene ontology for this factor
is identical to that for the ER factor with the exceptions that ‘‘cell
proliferation’’ and ‘‘DNA replication initiation’’ are replaced by
‘‘nuclear division’’ and ‘‘M phase’’. For all gene ontologies listed in
the top eight for these two factors, the Bayes factors are $10.
Because of the high degree of similarity in the gene ontology, it is
tempting to try to equate these two factors. Figure 2c shows a
scatterplot of the activity of the tumors in the data from [21] on
each of the two factors. The p53 factor is significantly bimodal,
and the mild correlation one can see is due entirely to this
bimodality, as tumor samples with high ER factor activity are
more likely to be in the second mode of the p53 factor. We
theorize that this bimodality is associated with a particular subtype
of the p53 mutation. However, there is no evidence of
multimodality in the ER factor, and the p53 specific factor
predicts ER status poorly. Because of these differences, and
because cell replication is a complex process, it is likely that these
two factors are related to distinct features of cell development.
We stress that, if we restrain ourselves to considering the
original in vitro lactic acidosis signature, we have no ability to fit or
predict any of these biological phenotypes (Table 3). Additionally,
these factors were generated entirely without regard to the ER
status, PgR status, or p53 status of the samples. This is in contrast
to a more typical design in which signatures associated with
phenotypes are defined strictly based on genes with expression
profiles that match those phenotypes (for example [21]). This type
of design is plagued with difficulties that arise from the large
number of genes, out of the tens of thousands on an array, with
expression patterns that match any arbitrary phenotype. With
SFPA, we search for genes that are expressed together without
regard to phenotype, and we are therefore much less likely to be
plagued by false discovery (as proven by our out of sample
predictive accuracy).
Cross-Study Projections
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SFPA offers a technique for interrogating a single independent
tumor sample against any number of biologically determined
signatures, and then consequent linking of factors to phenotypes
may include clinically relevant outcomes such as patient survival
outcomes and drug response.
Factors improve prediction of breast cancer
survival. Subsets of the 67 factors were evaluated in Weibull
survival regression models using the SSS method to identify and
score models predicting survival. Each model in a resulting set of
highly scoring models produces fitted survival curves and also may
be used to predict survival for new samples. Bayesian analysis
mandates averaging predictions from such a set of models, and this
was done to result in Figure 4a. This shows fits of survival curves
for the training data set [21], together with out of sample
predictions in four of the other data sets for which information
regarding survival exists. Recall that these are data sets from quite
distinct and diverse studies, so we are assessing a model fitted to
one data set on four quite challenging out of sample validation
data sets. Though not described further here, the BFRM statistical
model analysis used by the SFPA also addresses issues of gene-
sample-study specific effects within the analysis and is able to
correct enough of the idiosyncracies and bias inherent in
microarray assays to retain predictive accuracy [19,31]. The
results demonstrate that the factorprofiles of these in vitro
environmental signatures can improve survival prediction
significantly across several test data sets. Similar results are
obtained for the prediction of metastasis-free survival.
Factors predict Tamoxifen response. Four of the breast
cancer data sets have clinical annotation pertaining to treatment
with Tamoxifen. Though the 67 factors are in no way specifically
targeted at Tamoxifen, we do know they are associated with
relevant biological pathways. From our 67 factors, we found that
Lactic Acidosis 1 is predictive of Tamoxifen resistance. It
differentiates metastasis-free survival in patients who received the
drug and shows no predictive ability in patients who did not
(Figure 4b; the analysis underlying this followed the same
approach as for survival discussed above). Because all of the
patients who received Tamoxifen were ER positive, drug
resistance associated with this factor must be independent of the
antagonistic action of the drug on estrogen receptors. Since none
of these data sets were used in the training of the factor model, the
ability of these factors to distinguish resistance to Tamoxifen is
remarkable and demonstrates that they are robust to the collection
biases often seen in microarray experiments. We again used
GATHER to study the ontology of the genes included in this
factor (Table 4). This connects with the known association of
Tamoxifen with phosphate transport [32,33] as well as cell
adhesion [34,35]. In particular, Cowell et al. report that p130Cas/
BCAR1 is a cell adhesion molecule that promotes resistance to
Tamoxifen via a particular phosphorylation pathway. In addition
to these connections to the secondary effects of Tamoxifen is the
well-known connection between survival of patients on Tamoxifen
and toxicity associated with blood coagulation [36]. Further study
of the genes in this factor may lead to insight into the mechanism
behind Tamoxifen resistance in ER positive breast cancer.
Discovery of organ-specific factors from lactic acidosis
signatures. While the same biological processes may contribute
to tumor phenotypes in different cancers, the process by which this
happens may be entirely different given the particular cellular
context, tissue-specific gene expression and epigenetic influences.
Since SFPA can utilize in vivo cancer gene expression to dissect the
in vitro-generated gene signature, it offers the possibility of
identifying tissue and organ-specific factors associated with the
same gene signatures. This application has the potential to
distinguish sub-pathways that are conserved across many tissue
types from those that are organ-specific. To illustrate this point, we
utilize the lung cancer data set published in [11] and the ovarian
cancer data set from [10]. We obtained the lung cancer data from
GEO and the ovarian cancer data from the Duke Integrative
Cancer Biology Program (ICBP) web site (http://data.cgt.duke.
edu/platinum.php). We performed SFPA analysis of the same
lactic acidosis signature as a starting point for factor discovery
from the lung and ovarian cancer data sets.
In the case of the lung cancer, the analysis discovered 20 factors
associated with lactic acidosis. When we compared the expression
levels of the 10 lactic acidosis factors in the breast cancer data with
the 20 lactic acidosis factors discovered in the lung cancer data, we
found that several factors are highly conserved, including the
tamoxifen factor, the p53 specific factor, as well as factors 7 and 8.
In contrast, the ER and PgR factors are only found in breast
cancers. If we look specifically at standardized raw expression
levels for the genes in the ER factor in the breast data (figure S3a)
as compared to that for the lung data (figure S3b) we see that there
is consistent variation in the breast data which is not present in the
lung data. In contrast, the standardized raw expression for the
conserved tamoxifen factor shows a coherent expression pattern in
both breast (Figure S3c) and the lung cancers (Figure S3d).
Additionally, within this data set, our newly discovered factors also
possess significant prognostic value, being able to distinguish
between the two types of cancers (Figure S4a) as well as distinguish
between high and low risk patients (Figure S4b). Similar
observations are also present in ovarian cancer since the model
averaged survival using the 8 lactic acidosis factors discovered in
the ovarian cancer dataset can clearly differentiate high versus low
acuity patients (Figure S4c). Additionally, we see the same patterns
of loss of the ER factor (Figure S5(a,b)) and conservation of the
tamoxifen factor (Figure S5(c,d)). Finally, we find that the exact
same three factors, the p53 specific factor, factor 7, and factor 8,
have analogous factors in the ovarian cancer data with greater
than 90% correlation (as computed on the 251 breast cancer
samples).
Discussion
It is increasingly common for investigators to use gene
expression signatures directly as phenotypes to link various
biological processes and perturbations to disease phenotypes and
chemical agents. Although these signatures derived in vitro offer a
way to understand the in vivo biology, there is still considerable
limitation due to the differences between these two settings. Here,
we have exemplified a statistical approach to further improve the
in vitro gene signatures based on the gene expression in in vivo
Figure 2. Estrogen receptor factor: Derivation and associaions. Each point in these plots represents a single patient from the dataset in [21].
(a) Pairwise scatterplots of factors Acidosis 1, Hypoxia 4, Lactic acidosis 2, and Lactosis 5 of the sixty-seven factors. Each of these factors is derived
from a different starting signature and they are important and exchangeable in the prediction of ER status. The plots on the diagonal axis show
histograms of the scores on the respective factors. (b) Three is no significant correlation between the ER and PgR factors. (c) The ER and p53 factors
show some evidence of a relationship, but have clearly different structures (values shown are for activity of the respective factors in the data from
[21]).
doi:10.1371/journal.pone.0004523.g002
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original signatures can, as we have seen, improve the in vivo
relevance by more fully describing the diversity of in vivo expression
patterns. This may enhance prognostic value and provide
mechanistic insights into how biological processes affect clinical
phenotypes. As an example, we have found direct links between
factors generated by the use of SFPA on the lactic acidosis
signature. Such links are intriguing, and open questions regarding
causation as well as questions about the biological associations of
the remaining factors. However, regardless of links to known
biology, this strategy and analysis seem to provide an advance in
our ability to obtain consistent results across many different data
sets collected at different times by different groups. This is a
significant advance, as data collection inconsistencies are one of
the main roadblocks to the use of microarrays in a clinical setting.
There are several possible explanations for the enhancement of
the prognostic values achieved with SFPA. It is possible that
certain genes or pathway components in the original gene
signatures are simply noise or artifact due to their in vitro origins.
These genes may offer no or even negative prognostic values for in
vivo biology. By using SFPA to separate different components, it is
possible to enhance the prognostic value by selecting only the
relevant components or genes for predictive purposes. By so doing,
it is also possible to examine the genes comprising those factors
with strong links to clinical phenotypes which will lead to
biological insights into this association.
Another opportunity this analysis raises is the ability to uncover
the pathways which would be ‘‘hidden’’ in the in vitro signature. In
our current study, factor one was not immediately recognizable as
a clinically relevant list of genes, but the ability of this factor to
predict patient resistance to Tamoxifen points to an important
connection which would not have been possible to discern
otherwise. This observation will lead to efforts in investigating
the biological roles of this factor and how it is related to Tamoxifen
treatment and cellular response to lactic acidosis. For example, it is
well known that tumor hypoxia negatively impacts clinical
outcomes, but the actual mechanism by which this occurs is
complex and may include radiation resistance, increased tumor
invasion, migration, increased survival and decreased drug
sensitivities [37]. Although these hypoxia-induced effects occur
in cancer patients, many of these events cannot be replicated or
modeled in any particular in vitro setting. It is possible to uncover
these processes via of the use of SFPA for the cancer gene
expression. In a similar fashion, it is unclear how lactic acidosis
responses are linked to good prognosis [8], and SFPA will allow us
to explore in vivo gene expression to dissect this response and
develop testable biological hypotheses. Equally importantly, the
mechanisms by which hypoxia and lactic acidosis link to different
clinical outcomes may vary among different cancer types, and the
use of SFPA can specifically pinpoint the relevant biological
processes to target or intervene to modulate clinical courses of
cancer patients.
Tremendous resources continue to be expended on the
discovery of biomarkers for drug susceptibility. The ability to
predict susceptibility to a given drug has the potential to
significantly increase efficacy while decreasing morbidity and
mortality in the relevant patient population. Additionally, it opens
the possibility of facilitating the process of bringing new drugs to
market. We have demonstrated the efficacy of SFPA for
translating signatures discovered in vitro into factors which are
clearly related to specific biological processes and which can be
used to assess important clinical outcomes. The factors may be
Figure 3. Factor – phenotype relationships. ER and PgR factors predict progesterone receptor status: (a) training data set [21]; (b) projected into
the Wang data. Outcomes are PgR2 (blue, obs=0) and PgR+ (red, obs=1). The ER factors (Acidosis 1, Hypoxia 4, Lactic Acidosis 2, or Lactosis 5): (c)
training set [21], strongly associated with ER status; (d) projected into the tumor expression data from a completely different study – the Wang data
set in this case 25 – are able to predict ER status. Outcomes are ER2 (blue, obs=0) and ER+ (red, obs=1). (e) p53 status prediction, with outcomes
p53 wild type (blues, obs=0) and mutant (reds, obs=1) split between training (dark blue and red) and test/validation (light blue and pink) samples.
doi:10.1371/journal.pone.0004523.g003
Table 1. Gene Ontology of the ER Factor.
Gene Ontology # Genes p-value Bayes Factor
Cell Cycle 34 ,.0001 28
Cell Proliferation 39 ,.0001 25
Regulation of cell cycle 21 ,.0001 17
Mitotic cell cycle 15 ,.0001 16
We use GATHER to identify the collection of probes that have .99% probability
of inclusion in the ER factor. There is, not surprisingly, a high level of enrichment
of cell cycle genes in this factor. Bayes Factors and p-values are reported by
GATHER, see [29] for details.
doi:10.1371/journal.pone.0004523.t001
Table 3. Phenotype Associations with Factors and Signature.
LA Factors LA Signature
P53 Mutant P53 Wild P53 Mutant P53 Wild
.50% 63 5 23 10
,50% 9 174 49 169
ER+ ER2 ER+ ER2
.50% 202 17 212 31
,50% 11 17 1 3
PgR+ PgR2 PgR+ PgR2
.50% 180 33 185 54
,50% 10 28 5 7
Cross tabulation for prediction of three pheontypes by lactic acidosis factors
(left) and by the lactic acidosis signature (right). There is a mild correspondence
between lactic acidosis signature score and P53 status, while the best model for
predicting ER or PgR status from the lactic acidosis signature involves assuming
that all samples are positive (essentially the null model).
doi:10.1371/journal.pone.0004523.t003
Table 2. Gene Ontology of the PgR Factor.
Gene Ontology # Genes p-value Bayes Factor
Nucleotide Metabolism 6 .0004 4
RNA Processing 8 .0008 4
RNA Splicing 5 .003 2
Nulcear mRNA splicing 5 .003 2
RNA metabolism 8 .003 2
The gene ontology from GATHER for the probes with .99% probability of
inclusion in the PgR factor.
doi:10.1371/journal.pone.0004523.t002
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in a clinical setting), and remain consistent across many different
data sets. We do view this as a useful step ahead in thinking about
how gene expression genomics will advance us towards the goals of
personalized medicine.
Methods
A total of five signatures were derived from two different
experiments on Human Mammary Epithelial Cells (HMEC). The
details of the collection of gene expression data from these cell lines
are in [8]. Signatures from these experiments were derived using
the Bayesian Factor Regression Modeling (BFRM) software
detailed in [19], and that has been used in multiple previous
analyses of similar data [31,38]. The workspaces used for BFRM
are available in the supplementary materials S1, S2, and the
software is publicly available [20].
In designed experiments such as [8], BFRM provides a sparse
ANOVA framework for studying changes associated with
environmental stresses. It includes functionality for correcting
systematic laboratory bias which come about due to differences in
conditions under which the microarray data is collected. These
systematic differences are reflected in the doping control genes,
which are used to construct the correction factors.
Sparse Regression for Experiments with Known Variation
BFRM is a Bayesian modeling framework. As such, we assume
that all of the parameters of our model are random variables. In
order to learn more about the values of these parameters, we
specify prior distributions, which are subsequently updated based
on the data. The result of fitting the model to data in this way is a
joint posterior distribution for all of the model parameters. In our
case, the parameters of interest are the coefficients of the
regression.
The general model implemented in BFRM is as follows. Let x
be a matrix of expression values where (row g, column i) xg,i is the
expression of gene g from sample i where 1ƒiƒn. Denote the
design matrix (describing known sources of variability) by H
having elements hi,j on sample i and design or regression variable
j. The model may be written as a separate linear regression for
each probe on the array:
xg,i*N
X
j
bg,jhi,j,yg
 !
Or alternatively in matrix notation
X*BHzY
where B is a matrix of regression coefficients having elements bg,j
and Y is a diagonal covariance matrix with non-zero diagonal
elements yg. We allow the regression coefficients to vary across
both genes and design vectors ,but assign them a sparsity prior,
bg,j* 1{p ðÞ d0zpN 0,t ðÞ . We define ^ b bg,j to be the posterior mean
for bg,j, p 
g,j to be the posterior probabilities on non-zero values of
the bg,j, and ^ Y Yg to be the posterior mean of Yg. All of these
parameters are computed automatically by BFRM (along with
many others).
We have used a prior distribution for the coefficients of the
regression that has a point mass at zero. This reflects our belief
that, for any particular intervention, there will be relatively few
genes (of the over ten thousand that are measured in a microarray
experiment) that are affected. For the case outlined in this paper,
we argue that growing mammary epithelial cells in the presence of
mild lactic acidosis has led to changes in the expression of some of
the genes on the array, but that most remain unchanged. Thus our
posterior distribution for each bg,j will consist of a probability that
the parameter is non-zero (corresponding to a probability that the
gene is differentially expressed in the lactic acidosis experimental
group versus the control group), along with a distribution on the
magnitude of that possible change.
The prior on t is assumed to be a diffuse inverse gamma
distribution (which is a standard conjugate prior), and the prior on
p is also given a point mass mixture prior, reflecting the belief that
we must maintain significant mass around the extremes (zero and
one) even after updating with all of the probes on the chip
(50,000+). The precise values of all hyper-parameters are available
in the parameter files in the supplementary section.
We define a signature to be a list of genes and associated
weights. Using the posterior parameters from above we define the
weight of gene g for experimental group (design variable) j to be
sg,j~p 
g,j^ b bg,j
.
^ Y Yg. Calculation of the level of activity of a known
signature within a tumor sample requires that we initially subtract
Figure 4. Predicting survival and drug response. (a) Predicted survival times from an average of Weibull survival models where used to split the
251 samples from [21] according to above/below median predictions, and the resulting empirical survival curves (Kaplan Meier curves) are shown.
The red/blue stratification of patients is from the analysis using subsets of the 67 factors (red - high risk 50%, blue low risk 50%); the grey curves are
from the same analysis using all of the original five signatures (thus there is no compensation for over-fitting here). The p-values in each of the plots
correspond to stratification by factor analysis (top, black) and stratification using the signatures (bottom, grey). Data from [21] was used to identify
the survival models, therefore this plot represents fitted values. The four additional plots represent prediction in the four different breast tumor
samples based on the analysis of only the training data. The predictive relevance, and importance, of the factors is evident and consistent across
studies, and consistently improves on that achieved by use of signatures alone. (b) The first Lactic Acidosis factor predicts survival in patients who
were treated with Tamoxifen (left half), but shows no predictive value in patients who did not receive the drug (right half). In all of these figures, p-
values represent significance in a cox proportional hazards model.
doi:10.1371/journal.pone.0004523.g004
Table 4. Gene Ontology of the Tamoxifen Factor.
Gene Ontology # Genes p-value Bayes factor
Phosphate transport 6 ,.0001 8
Inorganic anion transport 6 .0002 5
Cell adhesion 11 .0002 5
Anion transport 6 .0003 4
Response to abiotic stimulus 8 .0008 4
Response to external stimulus 15 .001 3
Blood coagulation 4 .002 3
The gene ontology from GATHER for the probes with .99% probability of
inclusion in the Tamoxifen specific factor.
doi:10.1371/journal.pone.0004523.t004
Cross-Study Projections
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with BFRM exactly as above with the exception that the design
matrix contains only the intercept vector and correction factors (no
design vectors). If ym is a p-dimensional vector of corrected
expression values associated with tumor sample m, then the
signature score of signature sj in sample m is the weighted average P
g
sg,jyg,m.
Analysis of Breast Cancer Data Sets
We use six cancer data sets with Affymetrix U133+ expression
samples available on the Gene Expression Omnibus (GEO) web
site. Details of the collection and measuring are contained in
[21,25–28]. For all but Wang, Affymetrix .CEL files were
available, and we computed RMA normalized values in these
cases. For the data set from [27], we used MAS5 normalized data
which was obtained from the authors.
Statistical factor analysis using BFRM estimates latent factors
that represent common, underlying aspects of covariation of
subsets of genes, typically representing expression gene-by-gene in
terms of contributions from possibly several factors. The iterative
analysis to expand on an initial set of signature genes that we used
here then revises the gene list by adding in genes apparently
associated with estimated factors, and then refitting the model. Full
details of this algorithm are available in [19,20]. To choose a
collection of seed genes associated with experimental group j,w e
identify all genes, g, such that p 
g,jw:99. From this list of genes, we
take the 25% with the highest absolute change in expression level
between the control group and the corresponding experimental
group (as measured by the posterior ^ b bg,j). Following this
procedure, we obtain between 20 and 200 ‘‘seed’’ genes for factor
analysis.
Given a signature, we must choose a collection of tissue samples
on which to train the factor model. Because of its relatively large
size, the availability of CEL files, and the wealth of clinical and
phenotypic information, we chose the data set from [21] for the
identification of factors. We have five sets of seed genes, obtained
as described above, from experiments on HMEC’s. For each of
these five sets of genes, we independently use BFRM to obtain the
factors that are represented. We limited the number of genes to
recruit into factors to a total of 500.
To fit our binary regression and survival models, statistical
analysis used Shotgun Stochastic Search (SSS) routines from
[22,23]. Initialization files used by SSS for these searches are
included in the supplementary materials S1, S2. All Kaplan-Meier
curves showing differential survival are drawn by separating
samples at the median of the score that is relevant for that figure.
Statistical Factor Models for Tumor Expression Data
Factor models are structured as in [16]. If xi represents the
column vector of gene expression measures on p genes as assayed
in a single tumor, xi is regressed linearly on a combination of an
overall intercept term and assay correction factor, plus a set of
latent (i.e., to be estimated) factors. If hi is the column vector of
known regressors (the intercept and assay correction terms) on
tumor i, the model is of the form
xi~AlizBhizni, ni*N 0,Y ðÞ
where li is a column vector of unknown latent factor values on
tumor i, and A,B are coefficient matrices. In the BFRM context,
both A and B are large ‘‘tall and skinny’’ matrices with many more
rows (genes) than columns (the number of regressors and factors),
and are described by the same sparsity probability
models introduced above for the elements of B (inducing many
zeros).
Implicit in this formulation is the assumption that there is a set
of vectors, equivalent to design vectors, which describe some part
of the variation observed in the matrix of expression values, X.
This leads to the grouping of probes in a way that is comparable to
clustering, whereby we assign genes corresponding to non-zero
values in any particular column of A to the same group. This is
exactly parallel to sparsity in the coefficients associated with the
design vectors in that we are assuming that most genes are not
differentially expressed with any single latent factor.
Calculation of the activity of a set of factors, li on each tumor i,
and estimation of the factor loadings, A, is then a problem of
statistical estimation of the overall model. Details of these
calculations are available in [39]. The issue of projecting factors
to a new sample, lnz1, is then one of prediction that is
immediately available from the BFRM analysis framework
[19,20]. For completeness, we present the formula here:
l
 
new~ IdzA’Y{1A
  
A’Y{1: xnew{Bhnew ðÞ
Where l
 
new are approximations of the factor scores for a new
observation, with gene expression values xnew and design variables
hnew.
Supporting Information
Figure S1 We computed the significance of the relationship
between the lactic acidosis factors and the lactic acidosis signature
by resampling the lactic acidosis signature weights and modeling
the resulting scores with the factors. After 10,000 iterations, we fit
the sampled r-squared values to a beta distribution. This figure
shows a Q-Q plot of the distribution of resampled values versus the
best fit beta distribution. Using this beta distribution, we find that
the r-squared value from regressing the true signature scores on
the factors is significant with p-value approximately 1e-13.
Found at: doi:10.1371/journal.pone.0004523.s001 (0.03 MB JPG)
Figure S2 Percent of variation across all discovered factors as a
function of the number of principal components used.
Found at: doi:10.1371/journal.pone.0004523.s002 (0.01 MB
PNG)
Figure S3 Figures (a) and (b) show the expression levels of the
probes from the ER factor (discovered in breast tissue). (a)
shows a conserved pattern of expression in the breast samples
that is lost in the lung samples (b). (c) and (d) show the same
figure, but for probes from the Tamoxifen susceptibility factor.
For purposes of visualization, samples are sorted such that the
first principal component is increasing. In figures (a) and (c) the
rows are sorted according to increasing correlation with the first
principal component. The ordering of the rows in figures (b)
and (d) is forced to be the same as that in (a) and (c)
respectively.
Found at: doi:10.1371/journal.pone.0004523.s003 (0.64 MB
PNG)
Figure S4 Lactic acidosis factors discovered in lung cancer can
distinguish between adenocarcinoma and squamous cell carcino-
ma (a) as well as stratify patients according to rates of recurrence
(b). Factors discovered in ovarian cancer have similar prognostic
ability (c).
Found at: doi:10.1371/journal.pone.0004523.s004 (0.05 MB
PNG)
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pattern in breast cancer that is missing in the ovarian cancer data
set (a) and (b) while the tamoxifen susceptibility factor is conserved
across the two data sets.
Found at: doi:10.1371/journal.pone.0004523.s005 (0.48 MB
PNG)
Supplemental Materials S1 High dimensional sparse factor
modeling: Applications in gene expression gneomics. Reference 17
is currently in press, so we have included it as supplementary
material.
Found at: doi:10.1371/journal.pone.0004523.s006 (3.27 MB
PDF)
Supplemental Materials S2 In-vitro to in-vivo factor profiling
in expression genomics. Reference 37 is currently in press, so we
have included it as supplimentary material.
Found at: doi:10.1371/journal.pone.0004523.s007 (0.73 MB
PDF)
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